This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. Check our privacy policy here
Currently at SRB
News
Debiopharm Extends SunRock Biopharma Partnership for Antibody Drug Conjugates Targeting HER3 in EGFR Mutated Cancers
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today secured an…
Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-Treat Cancers
September 21, 2023 Debiopharm to boost its ADC oncology pipeline through multi-asset partnership with SunRock’s antibody portfolio integrating Multilink™ & AbYlink™…
Research activity starts in Santiago at the Sionlla Biopolo with the installation of SunRock and Zinpro
The company from Santiago de Compostela is searching for antibodies against cancer, while the multinational is working on animal welfare. The…
SunRock Biopharma and VHIO are beneficiaries of a project funded with 1.7 million euros for the development of new antibodies for the treatment of solid tumors
The initiative aims to advance the development of new therapeutic options for breast cancer, colorectal cancer, and head and neck cancer….
SunRock Biopharma and IDIS secure 1.8 million euros in funding for the IMPANC project.
This initiative aims to advance the study of a new and effective therapeutic alternative that improves the lives of pancreatic cancer…
SunRock Biopharma receives the Bioga Award as a Competitive BioCompany
The company’s experience and trajectory in the development of cancer treatments have made SunRock worthy of this recognition. The Business Technology…
Ellipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein
Ellipses Pharma granted exclusive global rights to develop and commercialise SRB22, in solid tumours LONDON and SANTIAGO DE COMPOSTELA, Spain,…
Events
